A Novel RNA In Situ Hybridization Assay for the Long Noncoding RNA SChLAP1 Predicts Poor Clinical Outcome After Radical Prostatectomy in Clinically Localized Prostate Cancer

Rohit Mehra; Yang Shi; Aaron M. Udager; John R. Prensner; Anirban Sahu; Matthew K. Iyer; Javed Siddiqui; Xuhong Cao; John Wei; Hui Jiang; Felix Y. Feng; Arul M. Chinnaiyan

doi:10.1016/j.neo.2014.11.006

A Novel RNA In Situ Hybridization Assay for the Long Noncoding RNA SChLAP1 Predicts Poor Clinical Outcome After Radical Prostatectomy in Clinically Localized Prostate Cancer

Rohit Mehra^*, Yang Shi, Aaron M. Udager, John R. Prensner, Anirban Sahu, Matthew K. Iyer, Javed Siddiqui, Xuhong Cao, John Wei, Hui Jiang, Felix Y. Feng, Arul M. Chinnaiyan

^*Corresponding author for this work

Anesthesiology

Research output: Contribution to journal › Article › peer-review

86 Scopus citations

Abstract

Long noncoding RNAs (lncRNAs) are an emerging class of oncogenic molecules implicated in a diverse range of human malignancies. We recently identified SChLAP1 as a novel lncRNA that demonstrates outlier expression in a subset of prostate cancers, promotes tumor cell invasion and metastasis, and associates with lethal disease. Based on these findings, we sought to develop an RNA in situ hybridization (ISH) assay for SChLAP1 to 1) investigate the spectrum of SChLAP1 expression from benign prostatic tissue to metastatic castration-resistant prostate cancer and 2) to determine whether SChLAP1 expression by ISH is associated with outcome after radical prostatectomy in patients with clinically localized disease. The results from our current study demonstrate that SChLAP1 expression increases with prostate cancer progression, and high SChLAP1 expression by ISH is associated with poor outcome after radical prostatectomy in patients with clinically localized prostate cancer by both univariate (hazard ratio = 2.343, P =.005) and multivariate (hazard ratio = 1.99, P =.032) Cox regression analyses. This study highlights a potential clinical utility for SChLAP1 ISH as a novel tissue-based biomarker assay for outcome prognostication after radical prostatectomy.

Original language	English (US)
Pages (from-to)	1121-1127
Number of pages	7
Journal	Neoplasia (United States)
Volume	16
Issue number	12
DOIs	https://doi.org/10.1016/j.neo.2014.11.006
State	Published - Dec 2014

Funding

Funding: This work was supported in part by the Prostate Cancer Foundation (R.M., F.Y.F, J.R.P. and A.M.C.), the National Institutes of Health Prostate Cancer Specialized Program of Research Excellence P50CA69568 to A.M.C., and the Early Detection Research Network (UO1 CA113913 to A.M.C. and U01CA113913 to J.W.). A.M.C. is also supported by the American Cancer Society,Alfred A. Taubman Medical Institute, and The Howard Hughes Medical Institute. F.Y.F. is supported by the Evans Foundation.

ASJC Scopus subject areas

Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.neo.2014.11.006

Cite this

Mehra, R., Shi, Y., Udager, A. M., Prensner, J. R., Sahu, A., Iyer, M. K., Siddiqui, J., Cao, X., Wei, J., Jiang, H., Feng, F. Y., & Chinnaiyan, A. M. (2014). A Novel RNA In Situ Hybridization Assay for the Long Noncoding RNA SChLAP1 Predicts Poor Clinical Outcome After Radical Prostatectomy in Clinically Localized Prostate Cancer. Neoplasia (United States), 16(12), 1121-1127. https://doi.org/10.1016/j.neo.2014.11.006

@article{9b1aa071041f465bbb4720186a2a6061,

title = "A Novel RNA In Situ Hybridization Assay for the Long Noncoding RNA SChLAP1 Predicts Poor Clinical Outcome After Radical Prostatectomy in Clinically Localized Prostate Cancer",

abstract = "Long noncoding RNAs (lncRNAs) are an emerging class of oncogenic molecules implicated in a diverse range of human malignancies. We recently identified SChLAP1 as a novel lncRNA that demonstrates outlier expression in a subset of prostate cancers, promotes tumor cell invasion and metastasis, and associates with lethal disease. Based on these findings, we sought to develop an RNA in situ hybridization (ISH) assay for SChLAP1 to 1) investigate the spectrum of SChLAP1 expression from benign prostatic tissue to metastatic castration-resistant prostate cancer and 2) to determine whether SChLAP1 expression by ISH is associated with outcome after radical prostatectomy in patients with clinically localized disease. The results from our current study demonstrate that SChLAP1 expression increases with prostate cancer progression, and high SChLAP1 expression by ISH is associated with poor outcome after radical prostatectomy in patients with clinically localized prostate cancer by both univariate (hazard ratio = 2.343, P =.005) and multivariate (hazard ratio = 1.99, P =.032) Cox regression analyses. This study highlights a potential clinical utility for SChLAP1 ISH as a novel tissue-based biomarker assay for outcome prognostication after radical prostatectomy.",

author = "Rohit Mehra and Yang Shi and Udager, {Aaron M.} and Prensner, {John R.} and Anirban Sahu and Iyer, {Matthew K.} and Javed Siddiqui and Xuhong Cao and John Wei and Hui Jiang and Feng, {Felix Y.} and Chinnaiyan, {Arul M.}",

note = "Funding Information: Funding: This work was supported in part by the Prostate Cancer Foundation (R.M., F.Y.F, J.R.P. and A.M.C.), the National Institutes of Health Prostate Cancer Specialized Program of Research Excellence P50CA69568 to A.M.C., and the Early Detection Research Network (UO1 CA113913 to A.M.C. and U01CA113913 to J.W.). A.M.C. is also supported by the American Cancer Society,Alfred A. Taubman Medical Institute, and The Howard Hughes Medical Institute. F.Y.F. is supported by the Evans Foundation. Publisher Copyright: {\textcopyright} 2014 Neoplasia Press, Inc.",

year = "2014",

month = dec,

doi = "10.1016/j.neo.2014.11.006",

language = "English (US)",

volume = "16",

pages = "1121--1127",

journal = "Neoplasia (United States)",

issn = "1522-8002",

publisher = "Elsevier Inc.",

number = "12",

}

Mehra, R, Shi, Y, Udager, AM, Prensner, JR, Sahu, A, Iyer, MK, Siddiqui, J, Cao, X, Wei, J, Jiang, H, Feng, FY & Chinnaiyan, AM 2014, 'A Novel RNA In Situ Hybridization Assay for the Long Noncoding RNA SChLAP1 Predicts Poor Clinical Outcome After Radical Prostatectomy in Clinically Localized Prostate Cancer', Neoplasia (United States), vol. 16, no. 12, pp. 1121-1127. https://doi.org/10.1016/j.neo.2014.11.006

TY - JOUR

T1 - A Novel RNA In Situ Hybridization Assay for the Long Noncoding RNA SChLAP1 Predicts Poor Clinical Outcome After Radical Prostatectomy in Clinically Localized Prostate Cancer

AU - Mehra, Rohit

AU - Shi, Yang

AU - Udager, Aaron M.

AU - Prensner, John R.

AU - Sahu, Anirban

AU - Iyer, Matthew K.

AU - Siddiqui, Javed

AU - Cao, Xuhong

AU - Wei, John

AU - Jiang, Hui

AU - Feng, Felix Y.

AU - Chinnaiyan, Arul M.

N1 - Funding Information: Funding: This work was supported in part by the Prostate Cancer Foundation (R.M., F.Y.F, J.R.P. and A.M.C.), the National Institutes of Health Prostate Cancer Specialized Program of Research Excellence P50CA69568 to A.M.C., and the Early Detection Research Network (UO1 CA113913 to A.M.C. and U01CA113913 to J.W.). A.M.C. is also supported by the American Cancer Society,Alfred A. Taubman Medical Institute, and The Howard Hughes Medical Institute. F.Y.F. is supported by the Evans Foundation. Publisher Copyright: © 2014 Neoplasia Press, Inc.

PY - 2014/12

Y1 - 2014/12

N2 - Long noncoding RNAs (lncRNAs) are an emerging class of oncogenic molecules implicated in a diverse range of human malignancies. We recently identified SChLAP1 as a novel lncRNA that demonstrates outlier expression in a subset of prostate cancers, promotes tumor cell invasion and metastasis, and associates with lethal disease. Based on these findings, we sought to develop an RNA in situ hybridization (ISH) assay for SChLAP1 to 1) investigate the spectrum of SChLAP1 expression from benign prostatic tissue to metastatic castration-resistant prostate cancer and 2) to determine whether SChLAP1 expression by ISH is associated with outcome after radical prostatectomy in patients with clinically localized disease. The results from our current study demonstrate that SChLAP1 expression increases with prostate cancer progression, and high SChLAP1 expression by ISH is associated with poor outcome after radical prostatectomy in patients with clinically localized prostate cancer by both univariate (hazard ratio = 2.343, P =.005) and multivariate (hazard ratio = 1.99, P =.032) Cox regression analyses. This study highlights a potential clinical utility for SChLAP1 ISH as a novel tissue-based biomarker assay for outcome prognostication after radical prostatectomy.

AB - Long noncoding RNAs (lncRNAs) are an emerging class of oncogenic molecules implicated in a diverse range of human malignancies. We recently identified SChLAP1 as a novel lncRNA that demonstrates outlier expression in a subset of prostate cancers, promotes tumor cell invasion and metastasis, and associates with lethal disease. Based on these findings, we sought to develop an RNA in situ hybridization (ISH) assay for SChLAP1 to 1) investigate the spectrum of SChLAP1 expression from benign prostatic tissue to metastatic castration-resistant prostate cancer and 2) to determine whether SChLAP1 expression by ISH is associated with outcome after radical prostatectomy in patients with clinically localized disease. The results from our current study demonstrate that SChLAP1 expression increases with prostate cancer progression, and high SChLAP1 expression by ISH is associated with poor outcome after radical prostatectomy in patients with clinically localized prostate cancer by both univariate (hazard ratio = 2.343, P =.005) and multivariate (hazard ratio = 1.99, P =.032) Cox regression analyses. This study highlights a potential clinical utility for SChLAP1 ISH as a novel tissue-based biomarker assay for outcome prognostication after radical prostatectomy.

UR - http://www.scopus.com/inward/record.url?scp=85003318605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85003318605&partnerID=8YFLogxK

U2 - 10.1016/j.neo.2014.11.006

DO - 10.1016/j.neo.2014.11.006

M3 - Article

C2 - 25499224

AN - SCOPUS:85003318605

SN - 1522-8002

VL - 16

SP - 1121

EP - 1127

JO - Neoplasia (United States)

JF - Neoplasia (United States)

IS - 12

ER -

A Novel RNA In Situ Hybridization Assay for the Long Noncoding RNA SChLAP1 Predicts Poor Clinical Outcome After Radical Prostatectomy in Clinically Localized Prostate Cancer

Abstract

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this